Ipsen S.A. (OTCMKTS:IPSEY) Receives Average Rating of “Hold” from Brokerages

Ipsen S.A. (OTCMKTS:IPSEYGet Free Report) has been given a consensus rating of “Hold” by the six brokerages that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company.

Separately, UBS Group raised shares of Ipsen from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 12th.

Read Our Latest Stock Analysis on Ipsen

Ipsen Stock Down 1.3 %

Shares of IPSEY stock opened at $29.71 on Wednesday. Ipsen has a 52 week low of $24.63 and a 52 week high of $34.34. The firm has a 50 day moving average of $32.01 and a 200-day moving average of $30.95.

Ipsen Company Profile

(Get Free Report

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma.

Further Reading

Analyst Recommendations for Ipsen (OTCMKTS:IPSEY)

Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.